

# 1 Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana

2 Peter Kojo Quashie<sup>1,2</sup>, Joe Kimanathi Mutungi<sup>1</sup>, Francis Dzabeng<sup>1</sup>, Daniel Oduro-Mensah<sup>1,3</sup>,  
3 Precious C. Oporum<sup>1</sup>, Kesego Tapela<sup>1,3</sup>, Aniefiok John Udoakang<sup>1</sup>, WACCBIP COVID-19  
4 Team<sup>1,3,4</sup>, Ivy Asante<sup>4</sup>, Lily Paemka<sup>1,3</sup>, Frederick Kumi-Ansah<sup>5</sup>, Osbourne Quaye<sup>1,3</sup>,  
5 Emmanuella Amoako<sup>6</sup>, Ralph Armah<sup>7</sup>, Charlyne Kilba<sup>7</sup>, Nana Afia Boateng<sup>7</sup>, Michael Ofori<sup>8</sup>,  
6 George B. Kyei<sup>4,9</sup>, Yaw Bediako<sup>1,2</sup>, Nicaise Ndam<sup>10</sup>, James Abugri<sup>11</sup>, Patrick Ansah<sup>12</sup>,  
7 William K. Ampofo<sup>4</sup>, Francisca Mutapi<sup>13</sup> and Gordon A. Awandare<sup>✉1,3</sup>

## 8 *Affiliations:*

- 9 1. West African Centre for Cell Biology of Infectious Pathogens, College of Basic and  
10 Applied Sciences, University of Ghana, Legon, Accra, Ghana
- 11 2. The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, United Kingdom
- 12 3. Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon,  
13 Accra, Ghana
- 14 4. Department of Virology, Noguchi Memorial Institute for Medical Research, University of  
15 Ghana, Legon, Accra, Ghana
- 16 5. Department of Microbiology, Cape Coast Teaching Hospital, Cape Coast, Ghana
- 17 6. Department of Pediatrics, Cape Coast Teaching Hospital, Cape Coast, Ghana.
- 18 7. Department of Internal Medicine, Surgery, Pediatrics and Emergency Medicine, Greater  
19 Accra Regional Hospital, Accra, Ghana
- 20 8. Immunology Department, Noguchi Memorial Institute for Medical Research, University of  
21 Ghana, Legon, Accra, Ghana
- 22 9. Medical and Scientific Research Directorate, University of Ghana Medical Centre, Legon,  
23 Accra, Ghana
- 24 10. UMR 216 MERIT-IRD, Université de Paris, France
- 25 11. Department of Applied Chemistry and Biochemistry, C.K. Tedam University of  
26 Technology and Applied Sciences, Navrongo, Upper East Region, Ghana
- 27 12. Navrongo Health Research Centre, Navrongo, Upper East Region, Ghana
- 28 13. NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA), and  
29 Institute of Immunology and Infection Research, School of Biological Sciences,  
30 University of Edinburgh, Ashworth Laboratories, King's Buildings, Charlotte Auerbach  
31 Road, Edinburgh, EH9 3FL, UK

32 *Corresponding Author*<sup>✉</sup>: Gordon A. Awandare (gawandare@ug.edu.gh)

33

34

35 **Abstract**

36 To estimate the level of community exposure to SARS-CoV-2 in Ghana, we conducted  
37 phased seroprevalence studies of 2729 participants in selected locations across Ghana.  
38 Phase I screening (August 2020) covered a total of 1305 individuals screened at major  
39 markets/lorry stations, major shopping malls, hospitals and research institutions involved in  
40 COVID-19 work. The screening was performed using a strip-in-cassette lateral flow type  
41 Rapid Diagnostic Test (RDT) kit that simultaneously and separately detected IgM and IgG  
42 antibodies against SARS-CoV-2 nucleocapsid protein. In Phase I, 252/1305 (19%) tested  
43 positive for IgM or IgG or both. Exposure rate was significantly higher among individuals  
44 tested at markets/lorry stations (26.9%) compared to those at Shopping Malls (9.4%). The  
45 41–60-years age group had the highest exposure rate (27.2%). People with only a basic  
46 level or no formal education had a higher exposure rate (26.2%) than those with tertiary level  
47 education (13.1%); and higher in informally employed workers (24.0%) than those in the  
48 formal sector (15.0%). Phases II and III screening activities in October and December 2020,  
49 respectively, showed no evidence of increased seroprevalence, indicating either a reduced  
50 transmission rate or loss of antibody expression in a subset of the participants. The Upper  
51 East region has the lowest exposure rate, with only 4 of 200 participants (2%) seropositivity.  
52 Phase IV screening in February 2021 showed that exposure rates in the upper income  
53 earners (26.2%) had almost doubled since August 2020, reflective of Ghana's second wave  
54 of symptomatic COVID-19 cases, which began in December 2020. The Phase IV results  
55 suggest that seroprevalence levels have become so high that the initial socioeconomic  
56 stratification of exposure has been lost. Overall, the data indicates a much higher COVID-19  
57 seroprevalence in the Greater Accra Region than was officially acknowledged, likely  
58 implying a considerably lower case fatality rate than the current national figure of 0.84%.  
59 Additionally, the high exposure levels seen in the communities suggest that COVID-19 in  
60 Ghana still predominantly presents with none-to-mild symptoms. Our results lay the  
61 foundation for more extensive SARS-CoV-2 surveillance in Ghana and the West African

62 sub-region, including deploying rapid antigen test kits in concert to determine the actual  
63 infection burden since antibody development lags infection.

64

65 **Background**

66 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in  
67 Wuhan, China, in late 2019 [1]. By April 20<sup>th</sup> 2021 there were 141,058,320 COVID-19 SARS-  
68 CoV-2 reported infections with 3,015,314 associated deaths (case fatality ratio (CFR): of  
69 2.1%) globally. Of these, 4,437,846 COVID-19 cases and 118,133 deaths (CFR: 2.7%),  
70 representing 3.07% and 3.85% of all reported global cases and deaths, were from the 55  
71 African Union Member States [2]. Ghana, from the first two reported (imported) cases on  
72 March 12<sup>th</sup> 2020, by April 16<sup>th</sup> 2021 reported a cumulative total of 91,709 confirmed cases  
73 with 771 associated deaths (CFR of 0.84%) by this date [3].

74 The current gold standard method for diagnosis of SARS-CoV-2 infection is by real-time  
75 reverse transcription polymerase chain reaction (RT-PCR), which detects viral nucleic acid  
76 sequences, and thus the virus, present in the upper respiratory tract (nasopharyngeal or  
77 oropharyngeal) swab samples [4-6]. Due to limited resources, tests are prioritised on  
78 symptomatic, severe, and/or suspected cases, and occasionally on contacts of confirmed  
79 cases. Common symptoms of SARS-CoV-2 infection include fever, dry cough, tiredness and  
80 other variable ones with onset between 5 to 14 days after infection [7]. Approximately 80%  
81 of infected persons show mild or no symptom [8], however, posing a danger of unmitigated  
82 transmission and potential rapid rise in disease onset, severity and death [9]. Additionally,  
83 RT-PCR sensitivity may be affected by viral load, virus replication rate, RNA isolation  
84 method, and the source or timing of swab collection relative to disease stage [10]. This could  
85 lead to false negativity of about 20% [11], indicating that actual infections may be higher  
86 than reported per test.

87 Rapid immunodiagnostic tests (RDTs) can be used to detect either SARS-CoV-2-expressed  
88 proteins (antigens) in respiratory tract samples (e.g., sputum, throat swab) or human anti-  
89 SARS-CoV-2 specific antibodies in blood or serum within minutes. Rapid antigen tests have  
90 utility for rapid detection of transmissible infections but have lower sensitivity than PCR-  
91 based methods [12] and have become common for routine SARS-CoV-2 screening at ports

92 of entry. Some RDTs also detect the presence of antibodies against SARS-CoV-2 in bodily  
93 fluids. These are useful for performing population level surveillance of viral exposure. Unlike  
94 antigen RDT's which pick up active and often transmissible infection, antibody RDTs tend to  
95 pick up the evidence of previous or recent infection and cannot be used to detect active  
96 infection [12]. There are more than 280 Conformité Européenne-*in vitro* diagnostics (CE-  
97 IVD)-marked COVID-19 antibody detection RDT kits listed with the Foundation for Innovative  
98 Diagnostics (FIND) [13]. Currently, lateral flow immunoassays (LFIAs), chemiluminescence  
99 immunoassays (CLIAs), or enzyme-linked immunosorbent assays (ELISAs) are commonly  
100 used for detection of SARS-CoV-2 IgM and IgG antibodies [14, 15]. Similar to other  
101 infections, SARS-CoV-2 elicits an immune response [16], and the presence of the virus-  
102 specific antibodies in blood indicates previous or current infection regardless of the presence  
103 or absence of symptoms [17, 18]. Generally, IgM or IgG are produced early and later in  
104 infection, respectively [19]. It is currently unknown how long SARS-CoV-2 IgM and IgG  
105 antibodies persist, however, seroconversion of IgM appears to peak simultaneously with IgG  
106 within 2 to 3 weeks after symptoms onset [10, 17, 20-24]

107 In addition to retrospectively evaluating infection dynamics and the population disease  
108 burden, serology tests are useful for vaccine trials, therapeutic antibodies results analyses,  
109 and tests for individual and herd immunity. Antibody presence can also help identify COVID-  
110 19-recovered individuals and potential donors of convalescent plasma for immunotherapy of  
111 critically sick COVID-19 patients [25]. Some seroprevalence studies have used cross-  
112 sectional snapshots to evaluate community level exposure of SARS-CoV-2 [26] but to our  
113 knowledge, no single study has attempted to track the spatial-temporal dynamics of SARS-  
114 CoV-2 exposure in Africa. Ghana reported its first two (imported) cases on March 12<sup>th</sup>, 2020  
115 [3]. By April 4<sup>th</sup>, positive cases who had neither travel history nor known contact with  
116 confirmed cases, were detected, implying local transmission. To estimate COVID-19  
117 community spread in Ghana, over a 7-month period, we randomly screened for IgM and IgG  
118 antibodies against SARS-CoV-2 in people at various public places in Accra (National capital,

119 where >50% of reported cases occur), Kasoa (a densely-populated town in the Central  
120 Region, and a COVID-19 transmission hotspot [27] and which shares a border with Accra),  
121 Cape Coast (Central Regional capital), Akropong (a small town in the Eastern Region, a 15-  
122 minute drive away from Accra), Navrongo (a small town in the Upper East Region, which  
123 hosts a public university and a government Health Research Centre) and Bolgatanga (the  
124 Upper East Regional capital) (Figure 1). A questionnaire administered during the study  
125 collected demographic data as well and evaluated the COVID-19 knowledge, attitudes and  
126 perceptions (KAP) of study participants.

127

128

129 **Methods**

130 *Study design*

131 This study was a multi-site repeated observational cross-sectional study carried out over a  
132 period of 7 months from July 27, 2020 to February 26, 2021. Phase I was performed  
133 between 27 July and September 14, 2020 (designated August 2020), followed by additional  
134 phases in October 2020, December 2020 and February 2021 to identify changes from the  
135 initial rates observed at public places (Figure S1). For ease of reference in the text, and for  
136 site anonymity, the sites were assigned codes based on site type and risk factors: markets  
137 and lorry stations (ML), malls (M), research centres (R), hospitals (H) and generalised  
138 community screening (C). Generalised community screening included attendees at a concert  
139 since that reflected individuals who would be otherwise dispersed through the community. A  
140 research centre involved in mass COVID-19 testing and a COVID-19 treatment centre were  
141 given the respective codes, RC and HC. Phase I participants were invited to volunteer for  
142 the study at two shopping malls, three major markets/lorry stations (ML1-3), two research  
143 institutes involved in COVID-19 work (R1) and COVID-19 testing (RC), and three major  
144 hospitals, one of which was a COVID-19 treatment centre (H1, H2, and HC). Informed  
145 consent was obtained from all study participants. Exposure to COVID-19 was detected using  
146 a strip-in-cassette lateral flow rapid diagnostic test kit which simultaneously detects IgM and  
147 IgG antibodies against SARS-CoV-2 antigens. Phase II screened participants at one market  
148 (ML4), one research centre (R1) and two hospitals (H1, H4) while Phase III screened  
149 participants at ML1 and across two towns in the Upper East Region (C1). During Phase IV,  
150 the exposure levels of upper-income earners were evaluated by screening at 2 malls (M1  
151 and M3) and a repeat screening at H2. In addition, the exposure level in a small town (C3) in  
152 the Eastern Region, near Accra, was estimated. Screening at hospitals and research  
153 facilities included only staff members and their close contacts; patients at the hospitals were  
154 excluded from this study. All tests were performed on-site and participants were  
155 subsequently informed of their exposure status and counselled to adhere to COVID-19

156 mitigation protocols. When IgM was detected, participants were referred for a COVID-19  
157 PCR test.

158

#### 159 *Testing kit*

160 The 'UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit' (Catalogue# UNCOV-40, Lot  
161 Number 20200326) was registered with the Ghana FDA, and the kit validation report was  
162 submitted to the Ghana Food and Drug Authority (FDA). For the validation exercise, sera  
163 from RT-PCR confirmed COVID-19 cases were used to evaluate several kits' performance  
164 since there were no established SARS-CoV-2 antibody detection standards for use at the  
165 commencement of this study. This kit had a manufacturer-declared IgG sensitivity and  
166 specificity of over 98% (<https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/634>).  
167 Using the Ghana Food and Drugs Authority (FDA) validation protocol<sup>36</sup>, the UNSCIENCE kit  
168 demonstrated a sensitivity of 66% when tested using 100 Ghanaian convalescent COVID-19  
169 patient sera (2-4 weeks after a PCR-positive result). We checked the existence of pre-  
170 existing cross-reactive antibodies using sera from 100 PCR-verified COVID-19 negative  
171 samples and obtained a specificity of 94%. In the validation exercises, when a test result  
172 was not obvious, at least 3 researchers validated the reading. In the rare case of an invalid  
173 test (no control line, or wrong location of bands), the test was repeated. A representative set  
174 of randomly chosen positive and negative test results are shown in Figure S2. The kit was  
175 also adjudged to have a concordance of 72% with the WHO-recommended Wantai ELISA kit  
176 (<https://www.fda.gov/media/140929/download>).

177

#### 178 *Data management and analysis*

179 A short questionnaire was administered to capture participant demographic data, knowledge  
180 of COVID-19 and COVID-19 testing history. The data, including the antibody test results  
181 were entered and managed using Research Electronic Data Capture suite (REDCap) [28].  
182 The data were cleaned by checking for completeness, duplication and consistency. Cleaned  
183 data were analyzed with Stata 16 (StataCorp, College Station, Texas, USA) and R/RStudio



184 [29, 30]. GraphPad Prism version 8.0.0 [31] was used for some additional analysis and  
185 generation of figures. Descriptive analyses were performed and univariate and multivariate  
186 logistic regression models were used to assess the association between seroprevalence and  
187 risk factors. Multivariable logistic models for seropositivity were obtained by using a  
188 backward stepwise procedure. Demographic variables that were associated with  
189 seropositivity at the  $P < 0.25$  level were included. The overall goodness of fit was assessed  
190 using the Wald statistic. Unadjusted and adjusted odds ratios with 95% confidence intervals  
191 were computed and presented as parallel dot plots with error bars. Statistical significance  
192 was inferred for  $p$ -values below 0.05.

193

194 **Results**

195 ***Study sites and participant characteristics***

196 A total of 2729 participants were screened for this study (Figure S1), including 1305 in  
197 Phase I (10 sites: August, 2020), 395 in Phase II (4 sites: October, 2020), 393 in Phase III (2  
198 sites: December, 2020) and 636 in Phase IV (4 sites: February 2021) . Altogether, four  
199 markets/lorry stations (ML-1 was visited twice), three malls (M1, twice), two research  
200 institutes (R, twice), two sets of small towns locations (C1 and C3) and four hospitals (H1  
201 and H2, twice) were screened across all Phases. During Phase III, 200 individuals were also  
202 screened from Navrongo and Bolgatanga in the Upper East Region (C1), which had the  
203 lowest reported COVID-19 cases in Ghana at the time the study began. Attendees (81) at a  
204 free Afrochella concert in Accra were also screened during Phase III (C2), potentially  
205 representing a general cross-section of the GAR population.

206 During Phase I, 946 individuals were sampled in public spaces, including 616 at  
207 markets/lorry stations and 330 at malls, while 359 were sampled in healthcare (254) and  
208 research (105) facilities (Table 1). There was a slightly higher number of female participants  
209 than males. The modal age range was 21–40 years, and over 40% of the participants had a  
210 tertiary education. Tertiary education was defined as having a post-secondary qualification  
211 such as a diploma, degree or above. Most respondents worked in the informal sector, with  
212 low or mid-level socioeconomic status. Over 90% of participants had good knowledge of  
213 COVID-19 symptoms, transmission routes and preventative measures (Figure S3). Such  
214 knowledge did not, however, correlate with participants' seropositivity status or mask-  
215 wearing prior to recruitment. Only 7% of participants had previously received a COVID-19  
216 PCR test (Figure S4). Similar participant characteristics were observed in Phases II, III and  
217 IV with smaller numbers of participants.

218 **Table 1: Socio-demographic characteristics of participants (N=2729)**

Characteristics	Phase 1 (n=1305)		Phase 2 (n=395)		Phase 3 (n=393)		Phase 4 (n=636)	
	number	Percentage	number	Percentage	number	Percentage	number	Percentage
<b>Exposure risk groups</b>								
Shopping malls (M)	330	25.3					356	56.0
Markets/Lorry stations (ML)	616	47.2	152	38.5	115	36.5		
COVID testing/treatment centres (RC/HC)	105	8.0						
Other Health Research centres/Hospital R/H	254	19.5	243	61.5			81	12.7
Navrongo/Bolgatanga (C1)					200	63.5		
Afrochella Concert (C2)					78	19.8		
Akropong (C3)							199	31.3
<b>Gender</b>								
Male	591	45.3	124	31.4	177	45.0	295	46.4
Female	714	54.7	271	68.6	216	55.0	341	53.6
<b>Age group (in years)</b>								
<21	63	4.8	13	3.3	63	16.0	44	6.9
21-40	769	58.9	216	54.7	251	63.9	362	56.9
41-60	365	28.0	119	30.1	57	14.5	167	26.3
60+	89	6.8	13	3.3	7	1.8	62	9.7

Characteristics	Phase 1 (n=1305)		Phase 2 (n=395)		Phase 3 (n=393)		Phase 4 (n=636)	
	number	Percentage	number	Percentage	number	Percentage	number	Percentage
Missing	19	1.5	34	8.6	15	3.8	1	0.2
<b>Educational level</b>								
None/Basic	402	30.8	128	32.4	117	29.8	202	31.8
Secondary	245	18.8	54	13.7	148	37.7	139	21.9
Tertiary	616	47.2	133	33.7	106	27.0	279	43.9
Missing	42	3.2	80	20.3	22	5.6	16	2.5
<b>Employment type</b>								
Formal	520	39.8	171	43.3	72	18.3	257	40.4
Informal	655	50.2	175	44.3	190	48.3	261	41.0
Student	59	4.5	21	5.3	114	29.0	48	7.5
Unemployed	44	3.4	19	4.8	11	2.8	70	11.0
Missing	27	2.1	9	2.3	6	1.5	0	0.0
<b>Socio-economic status</b>								
Lowest	524	40.2	170	43.0	158	40.2	249	39.2
Middle	259	19.8	122	30.9	78	19.8	124	19.5
Higher	522	40.0	103	26.1	157	39.9	263	41.4

219 ***Anti-SARS-CoV-2 seropositivity in Phase I***

220 In Phase I, SARS-CoV-2 IgG, IgM or both antibodies were detected in 19% of all participants  
221 (Figure 2A), with the highest rate amongst participants sampled in markets/lorry stations  
222 (27%). Among health workers, those at COVID-19 treatment/testing sites had higher  
223 exposure rates compared to their colleagues who were not directly handling COVID-19  
224 patients or samples. There was no significant difference in seropositivity across genders  
225 (Figure 2B). When stratified by age categories, the highest level of seroprevalence (27.1%)  
226 was observed in the 41–60 years age group (Figure 2C). Participants with higher  
227 educational backgrounds (Figure 2D), those employed in the formal sector (Figure 2E) and  
228 those with higher economic standing (Figure 2F) had lower exposure levels than participants  
229 with lower educational background, informal sector workers and poor economic background.  
230 Only 20.9% of seropositive participants reported having had COVID-19-like symptoms  
231 (Figure 3).

232 Logistic regression analysis was performed on data from Phase I to identify factors that  
233 correlated with increased risk of SARS-CoV-2 exposure (Figure 4). Univariate modelling  
234 showed that socio-demographic factors were significantly associated with increased or  
235 decreased exposure. These were: being sampled at either markets and lorry stations (Odds  
236 ratio, OR:3.6, 95% confidence interval, CI: 2.4-5.4) or a COVID-19 treatment/testing centre  
237 (OR: 2.4, 95% CI:1.3-4.4.), being employed in the informal sector (OR: 1.8, 95% CI:1.3-2.4)  
238 having a high education (OR: 0.4, 95% CI:0.3-0.6) or having a high income (OR:0.6, 95%  
239 CI:0.5-0.9). In a multivariate model, sampling location, participant educational level and  
240 income/socioeconomic status remained significantly associated with COVID-19 exposure  
241 status; participants were significantly more likely to have COVID-19 antibodies if they were  
242 sampled in markets/lorry stations (adjusted odds ratio, aOR: 2.5, 95% CI: 1.5-4.2), and  
243 COVID-19 testing/treatment centre (aOR:3.6, 95%CI:1.7-7.5). Participants who had basic or  
244 no formal education (aOR: 0.8, 95% CI: 0.5-1.3) had a higher risk of COVID-19  
245 seropositivity. Unemployed individuals (aOR: 0.7, 95% CI: 0.2-2.1) (Table 2, Figure 4), those

246 with high educational level (aOR: 0.8, 95%CI: 0.5-1.3) and high socioeconomic status (aOR:  
247 0.8, 95%CI: 0.6-1.2) had reduced risk of COVID-19 seropositivity, but these associations  
248 were not statistically significant (Table 2, Figure 4).

Table 2: Summary of participant seropositivity status (N=2729)

	August 2020 (n=1305)		Oct 2020 (n=395)		Dec - 2020 (n=393)		Jan- Feb 2021 (n=636)	
	Number	Antibody Positivity	Number	Antibody Positivity	Number	Antibody Positivity	Number	Antibody Positivity
	Sampled	%	Sampled	%	Sampled	%	Sampled	%
<b>Sampling location (Code)</b>								
Shopping malls (M)	330	9.4					356	25.3
Markets/Lorry stations (ML)	616	26.9	152	19.7	115	23.5		
COVID testing/treatment Centres (RC/HC)	105	20.0						
Health Research Centres/Hospital (R/H)	254	13.4	243	14.0			81	22.2
Navrongo/Bolgatanga (C1)					200	2.0		
Afrochella Concert (C2)					78.0	15.4		
Akropong (C3)							199	18.6
<b>Gender</b>								
Male	591	18.1	124	14.5	131	1.7	10.7	22.7
Female	714	20.3	271	17.0	184	2.8	11.1	22.9
<b>Age group (in years)</b>								
4-21	63	17.5	13	0.0	63	11.1	44	9.1
21-40	769	16.1	216	11.1	251	11.6	362	24.9
41-60	365	27.1	119	21.8	57	10.5	167	22.8
60+	89	18.0	13	38.5	7.0	14.3	62	21.0
Missing	19	10.5	34	26.5	15	0.0	1	0.0

	August 2020 (n=1305)		Oct 2020 (n=395)		Dec - 2020 (n=393)		Jan- Feb 2021 (n=636)	
	Number	Antibody Positivity	Number	Antibody Positivity	Number	Antibody Positivity	Number	Antibody Positivity
	Sampled	%	Sampled	%	Sampled	%	Sampled	%
<b>Educational level</b>								
None/Basic	402	26.6	128	22.7	117	12.0	202	17.8
Secondary	245	24.5	54	14.8	148	11.5	139	25.9
Tertiary	616	13.5	133	15.0	106	10.4	279	24.7
Missing	42	4.8	80	8.8	22	4.5	16	25.0
<b>Employment type</b>								
Formal	520	15.0	171	11.7	72	6.9	257	23.7
Informal	655	24.0	175	20.6	190	13.7	261	24.9
Student	59	16.9	21	4.8	114	9.6	48	12.5
Unemployed	44	9.1	19	21.1	11	0	70	18.6
Missing	27	11.1	9	33.3	6	16.7		
<b>Socio-economic status</b>								
Low	524	23.1	170	17.1	158	15.8	249	18.1
Middle	259	19.7	122	15.6	78	10.3	124	25.0
High	522	15.3	103	15.5	157	6.4	263	26.2
	IgG	13.0	IgG	15.2	IgG	9.7	IgG	22.8
	IgM	1.6	IgM	1.3	IgM	2.3	IgM	2.2



### 251 ***Phases II and III: Targeted follow-up seroprevalence surveys***

252 As follow-ups to Phase I, the trend of population seroprevalence was again investigated in  
253 Phase II and III. Two months after the initial public places screening (October, 2020), 144  
254 individuals were screened at a lorry station in Accra and 212 participants at two hospitals in  
255 Accra and Cape Coast. Overall, seroprevalence at the lorry station was 19.7%, and 13% at  
256 the two hospitals. The H4 facility staff had higher (18.5%) seroprevalence level than those at  
257 H1, previously sampled in Phase I. A Phase III screening exercise was conducted at M1,  
258 which was originally sampled in Phase I, and that showed an estimated seroprevalence of  
259 23.5%. Additionally, 200 individuals were screened in the Upper East Region (C1), an area  
260 with low population density and very few reported COVID-19 cases at the time. Here, 4 out  
261 of 200 individuals (2%) tested positive for SARS-CoV-2 antibodies (Table 1). Individuals  
262 screened at the Afrochella concert (C2) showed an estimated seroprevalence of 16%, which  
263 was similar to the Phase I data, with the HC site excluded.

### 264 ***Phase IV: Impact of the second wave***

265 Beginning in late December 2020, large numbers of symptomatic COVID-19 cases started to  
266 be detected at hospitals and treatment centres in Accra and other major cities. The patients  
267 were mostly of high socio-economic standing [32]. We therefore performed repeat screening  
268 at M1 and H2 (both sampled in Phase I) and sampled again at M3 and a small town in the  
269 Eastern Region (C3). The average seroprevalence at the two malls (M1 and M3) was at  
270 27%, whilst H1 and C3 recorded 25% and 17% respectively.

### 271 **Discussion**

272 This study was necessitated by a dearth of epidemiological data on COVID-19 prevalence in  
273 Ghana. In the first few months of the pandemic when prevalence was low, Ghana ranked  
274 high among African countries, and even globally, for administering high numbers of tests per  
275 million people [33]. To meet the high demand for testing, Ghana's main testing centre,  
276 Noguchi Memorial Institute for Medical Research, employed "sample pooling" methods [34-

277 37]. However, since then, Ghana has declined significantly to number 22 in tests per million  
278 of population in Africa [38]. Data from the Ghana Health Service's COVID-19 archives [3]  
279 indicates that testing has significantly reduced after peaking in June, correlating with a drop  
280 in daily reported cases. Among other factors, the reduced testing could be due to the fact  
281 that at the current positivity rate of 8.3% of tested cases, sample pooling is no longer a  
282 viable cost-cutting and test-rate enhancing measure. The seroprevalence rate average of  
283 19.3% obtained from our public screening exercises is probably a better reflection of SARS-  
284 CoV-2 infections in Ghana, especially in the large and densely populated urban areas.  
285 Additionally, currently, most RT-PCR tests in the country are administered to travellers,  
286 representing a higher economic tier of society. The relatively low (9.3%) seroprevalence  
287 initially observed in malls, assumed to be frequented by the higher tiers of society, may  
288 correlate well with the official 10% RT-PCR test positivity rate reported in September 2020  
289 [3].

290 Participants across all sites demonstrated good knowledge of COVID-19 risks, symptoms  
291 and preventive measures. This did not however translate into observation of protocols in the  
292 markets and lorry stations, where, by visual estimation, 10–50% of the study participants  
293 arrived mask-less and had to be requested to wear a mask donated by the study. This  
294 attitude corresponds with two surveys on mask-wearing, carried out by the Ghana Health  
295 Service which showed public mask wearing of ~40% and 10% in July and September,  
296 respectively [39, 40]. Our previous genomic study showed evidence of undetected  
297 community spread likely caused by asymptomatic individuals [27]. Of note, nearly 80% of  
298 people who were seropositive did not report significant COVID-19 symptoms (Figure 3),  
299 confirming that SARS-CoV-2 infections in Ghana are predominantly asymptomatic,  
300 consistent with reported global trends [8]. With the 19.3% seroprevalence in the Greater  
301 Accra Region (GAR), we inferred that nearly 1 million out of the estimated 5 million GAR  
302 residents may have already been exposed to SARS-CoV-2. This staggering number  
303 suggests that the actual fatality rate of COVID-19 in Ghana may be much lower than the

304 reported CFR of 0.7%, since that would have translated to approximately 7000 deaths in a  
305 large metropolis like Accra, which would have been rather very obvious . Additionally, there  
306 was no evidence of a stressed or panicked healthcare system nor visible or anecdotal  
307 evidence of excess deaths during the Phase I hospital screening.

308 Given the higher-than-expected seroprevalence observed in the Greater Accra Region,  
309 follow-up surveys were conducted at some of the Phase I locations as well as other parts of  
310 the country to confirm the findings and obtain vital information about infection dynamics over  
311 time. Repeated screening of markets and lorry stations in October and December yielded  
312 seroprevalence rates of 19.7% and 23.5%, respectively. The seeming plateau in  
313 seroprevalence in lower socioeconomic status individuals may be indicative of, either a  
314 peaking of infections -coincident with the onset of Phase I seroprevalence [3], or loss of  
315 antibody expression in some section of the population over time. Phase II surveys at the  
316 health and research facilities which were not directly handling patients or testing samples, in  
317 October, also showed a similar overall seroprevalence (13%), as observed in August.  
318 Participants in Navrongo and Bolgatanga in the Upper East region (C1), with some of the  
319 lowest reported cases, showed very low (2%) seroprevalence, confirming the reliability of  
320 this study. Consistent with global reports, participants in the 40-60 and 60+ year age groups  
321 exhibited the highest seroprevalence levels across all 3 phases (Figure 4, S4, S5). The  
322 results of Phase IV reflected the high levels of new COVID-19 cases and hospitalisations in  
323 Ghana, mainly in the middle socioeconomic class [32]. As such, it was not surprising that the  
324 socioeconomic divide in prevalence observed in Phase I had mostly disappeared and even  
325 appeared reversed by Phase IV.

326 Our observed seropositivity rates are in line with previous reports from other African  
327 countries[41, 42]. A study in Kenya estimated 20% SARS-CoV-2 seropositivity in adults  
328 (~1.6 million people) at a time when the total reported infections were 2093 (with  
329 approximately 90% asymptomatic cases) and 71 deaths of all ages [43]. The initial trend  
330 relating income disparity and COVID-19 seropositivity is not surprising. Even in countries

331 where lower seroprevalence was reported, such as China (1.63%), lower income status  
332 correlated with the highest seroprevalence (5.62%) [44], and this trend was initially reflected  
333 in this current study. The shift to high prevalence even in high socioeconomic brackets is  
334 likely due to poor adherence to COVID-19 protocols during the period of this study, likely  
335 due to election activities [45] and the 2020 Christmas/2021 New Year holiday festivities.

### 336 ***Strengths and Limitations of this study***

337 By surveying participants at different sites and times, representing categories of different  
338 perceived risk factors, this study obtained credible estimates for population-level prevalence  
339 across these sites and how that changed over the sampling period. This will allow future  
340 screening at these sites to determine the seroprevalence trends. However, most  
341 seroprevalence studies only reflect past disease burden. Using Markets and Lorry Stations  
342 enabled sampling of a broad cross-section of the Ghanaian populace.

343 Phase I of the study was conducted in the region with the greatest burden of reported  
344 infections and it was expected that a country-wide survey would yield less seroprevalence.  
345 Site H3, situated in the town of Cape Coast, a tourist hub and Central regional capital,  
346 exhibited a very high prevalence at 18.5% during Phase II, but this was not surprising given  
347 that M4, located in Kasoa, also in the Central Region, exhibited an exposure rate of 28%  
348 during Phase I. The low seroprevalence observed at C1 (2%) during Phase III hinted that  
349 community size/density may play a role in COVID-19 transmission. Given the geographical  
350 remoteness of C1 to the major hotspots of Accra and Kumasi, another small community (C3)  
351 in the country's Southern belt with higher population density was screened, yielding an  
352 observed prevalence rate of 17%, and showing that SARS-CoV-2 exposure is not just a  
353 metropolitan burden, but one that needs to be tracked across the country. This, however,  
354 does not rule out that towns with lower population densities and who are far from  
355 metropolitan areas may exhibit lower seroprevalence levels.

356 During validation, this kit showed a sensitivity of 66%, when compared to PCR positivity.  
357 This is despite the manufacturer reporting sensitivity and specificity values above 98%. The  
358 apparent lower than expected sensitivity observed in local validation could at least partly be  
359 due to weak or delayed antibody responses in some of the infected persons. The import of  
360 this is that the seroprevalence levels reported in this study are likely underestimates of true  
361 disease prevalence.

362 One oft-repeated concern with SARS-CoV-2 seroprevalence studies in Africa is cross-  
363 reactivity due to pre-existing antibodies to other viruses and vaccines [46]. Some studies  
364 have reported extensive cross-reactivity against SARS-CoV-2 in Africa [47]). However, most  
365 of these studies had limitations, and as such their conclusions are unreliable. These flaws  
366 include extremely small study sizes (below 500 and even sometimes below 100) [48], tend  
367 to be based at single institutions and/or cities [47] and use samples collected at widely  
368 divergent time periods for their 'Western' and 'African' pre-COVID-19 samples [48]. The  
369 UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit used in our study exhibited 94%  
370 specificity during validation (with plasma from 100 COVID-19 PCR-negative individuals).  
371 Antibody RDTs are contraindicated in cases of active fever, based on manufacturer's  
372 information leaflets, unpublished analyses and other studies [47]. We confirmed that none of  
373 the study respondents had temperature above 38, thereby reducing the likelihood of fever  
374 affecting the results.

375 Antibody cross-reactivity with other pathogens is often manifested in IgM detection [49, 50].  
376 During validation, and in the field, detection of IgM was uncommon, and when detected, IgM  
377 was often accompanied by IgG. This reduced the likelihood that those IgM detections were  
378 as a result of cross-reactivity. That said, a cross-reactivity rate of 6% with IgM was detected  
379 during validation. However, the test kit performed even better in the field; Navrongo and  
380 Bolgatanga in the Upper-East region of Ghana are towns with populations highly vaccinated  
381 against other pathogens, yet only 2% of 200 individuals (4 individuals) showed seropositivity  
382 in this study. This low seropositivity correlated well with the low level of reported COVID-19 in

383 those towns at the time and hinted that the rates observed in Accra and environs were due  
384 to the SARS-CoV-2 exposure rate, but not from cross-reactivity. Taken together, there is a  
385 low likelihood that cross-reactive antibodies played a significant role in this study.

### 386 **Conclusions and Recommendations**

387 This study highlights a relatively high level of SARS-CoV-2 infections in the Greater Accra,  
388 Central and Eastern Regions, but not in the Upper East region. Most of these infections  
389 were unreported and likely asymptomatic.

390 As one of the first studies with such depth and nuance, we provide some of the first  
391 evidence of low levels of symptomatic COVID-19 infection, previously only anecdotally  
392 reported. These findings imply that there is a need for increased enforcement of COVID-19  
393 mitigation protocols and more effective public education.

394 Large scale cross-sectional studies of seroprevalence across Ghana and West Africa may  
395 be a practical approach for disease tracking even as vaccines are being deployed<sup>55,56</sup>. The  
396 dynamism observed in demographic exposure risk over time highlights the need for  
397 continuous risk and prevalence assessments to track highly transmissible disease agents  
398 like SARS-CoV-2.

399 Finally, resources should be mobilised to research the molecular and immunological  
400 mechanisms underlying the apparent high tolerance to COVID-19 observed in Ghana, the  
401 West African sub-region, and Africa as a whole.

402

403

404 **Ethical Approval**

405 Procedures in this study conform with the Ghanaian Public Health Act, 2012 (Act 851) and  
406 the Data Protection Act, 2012 (Act 843). Ethical approval was received from the Ethics  
407 Board of the College of Basic and Applied Sciences, University of Ghana (ECBAS 063/19-  
408 20), and the Ethical Review Committee of the Ghana Health Service (GHS-ERC 011/03/20).

409

410 **Consent**

411 In line with the ethical protocol above, written informed consent was obtained for all study  
412 participants. Upon consent, each participant was assigned a unique identification number  
413 (ID). This ID was used for testing and data recording, thereby delinking participant  
414 identification with the test results and questionnaire answers. All consent forms are kept in a  
415 locked cabinet accessible to only the study PI and the WACCBIP Data Manager.

416 **Other WACCBIP COVID-19 Team members**

417 Kyerewaa Boateng<sup>1</sup>, Jerry Quaye<sup>1,3</sup>, Aaron Adom Manu<sup>1</sup>, Eugene Boateng<sup>1,3</sup>, Daniel  
418 Lorlorson Okpatah<sup>1,3</sup>, Louisa Baaba Obbeng<sup>1</sup>, Oforiwaa Ofori<sup>1,3</sup>, Peggy Afua Agypomaah  
419 Birikorang<sup>1,3</sup>, Simon Donkoh<sup>1</sup>, Sylvester Languon<sup>1,3</sup>, Stephen Kotei Kotey<sup>1,3</sup>, Alexandra  
420 Lindsey Zune Djomkam<sup>1,3</sup>, Adelaide Fierti<sup>1,3</sup>, Claudia Adzo Anyigba<sup>1,3</sup>, Nancy Nyakoe<sup>1,3</sup>,  
421 Felix Ansah<sup>1,3</sup>, Darius Quansah<sup>1,3,4</sup>, Sylvia Tawiah-Eshun<sup>1</sup>, Barikisu Anna Ibrahim<sup>1</sup>, Elizabeth  
422 Fosua<sup>1</sup>, Raymond Adjei<sup>1</sup>

423 **Author contributions**

424 GAA and FM conceived the study. GAA and PKQ designed the study, wrote the SOP for the  
425 fieldwork and supervised all aspects. YB, JKM, PCO, PKQ, WKA, AJU and some members  
426 of WCT performed validation of the kit. PKQ, JKM, PCO, DO-M, AJU, WCT, FK, EA, IA, LP,  
427 RA, CK, NAB, YB, JA, PA and GAA participated in seroprevalence screening activities. KB  
428 planned the site visits and partook in screening activities. PKQ, FD and PCO analysed the  
429 data. PKQ, JKM and GAA wrote the manuscript with additional editing by DO-M, YB, OQ and  
430 NN. All authors read and approved the final version of the manuscript before submission.

431 **Acknowledgements**

432 We are sincerely grateful to all study participants for their contributions. We also thank the  
433 leadership of the various malls, markets, medical and research centres who allowed  
434 screening on their premises. We are grateful to the WACCBIP staff, especially the public  
435 engagement team, for their assistance in planning the screenings at the study sites.

436 **Funding**

437 This study was funded by a Wellcome/African Academy of Sciences Developing Excellence  
438 in Leadership Training and Science (DELTAS) grant (DEL-15-007 and 107755/Z/15/Z:  
439 Awandare); National Institute of Health Research (NIHR) (17.63.91) grants using funding  
440 from the UK Government for a global research unit for Tackling Infections to Benefit Africa  
441 (TIBA partnership, University of Edinburgh); and the World Bank African Centres of  
442 Excellence grant (WACCBIP-NCDs: Awandare). PKQ and YB are supported by Crick  
443 African Network Career Accelerator fellowships (CAN/A00004/1 and CAN/A00003/1  
444 respectively). The views expressed in this publication are those of the authors and not  
445 necessarily those of the funders.

446 **Conflicts of Interest**


447 None to declare

448



449

450 **Figures**



451

452 **Figure 1: Map of Ghana showing study sites.** Figure was generated using QGIS (QGIS  
453 Development Team, 2009. QGIS Geographic Information System. Open Source Geospatial  
454 Foundation. URL <http://qgis.org>)

455

456


457

458

459

460

461



462

463 **Figure 2: SARS-CoV-2 seropositivity reported by (A) Sampling sites, (B) gender, (C)**


464 **Age, (D) Highest education level, (E) Employment status and (F) Socioeconomic**

465 **status.** Error bars reflect the standard error of measurement. Where relevant, p-values are

466 indicated as follows  $p < 0.05$ ; \*,  $p < 0.01$ ; \*\*,  $p < 0.001$ ; \*\*\*. Error bars, where relevant, represent

467 standard deviation across sites.


468



469

470 **Figure 3 Presence of two or more self-reported COVID-19 symptoms in seropositive**

471 **individuals in the month preceding the study.**



472

473 **Figure 4: Modelling of COVID-19 exposure risk across Phase I study participant**

474

475 **References**

476

- 477 1. World Health Organization. *Pneumonia of unknown cause – China*. January 5, 2020;  
478 Available from: [https://www.who.int/csr/don/05-january-2020-pneumonia-of-](https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/)  
479 [unkown-cause-china/en/](https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/).
- 480 2. *Africa CDC-Outbreak Brief 66: Coronavirus Disease 2019 (COVID-19) Pandemic*.  
481 April 20 2021; Available from: [https://africacdc.org/download/outbreak-brief-66-](https://africacdc.org/download/outbreak-brief-66-coronavirus-disease-2019-covid-19-pandemic/)  
482 [coronavirus-disease-2019-covid-19-pandemic/](https://africacdc.org/download/outbreak-brief-66-coronavirus-disease-2019-covid-19-pandemic/).
- 483 3. Ghana Health Service, G.H. *COVID-19 Updates*. 2020; Available from:  
484 <https://ghanahealthservice.org/covid19/archive.php>.
- 485 4. Chu, D.K.W., et al., *Molecular Diagnosis of a Novel Coronavirus (2019-nCoV)*  
486 *Causing an Outbreak of Pneumonia*. Clin Chem, 2020. **66**(4): p. 549-555.
- 487 5. Emery, S.L., et al., *Real-time reverse transcription-polymerase chain reaction assay*  
488 *for SARS-associated coronavirus*. Emerg Infect Dis, 2004. **10**(2): p. 311-6.
- 489 6. Loeffelholz, M.J. and Y.W. Tang, *Laboratory diagnosis of emerging human*  
490 *coronavirus infections - the state of the art*. Emerg Microbes Infect, 2020. **9**(1): p.  
491 747-756.
- 492 7. Organisation, W.H. *COVID-19 symptoms*. 2020 [cited 2021 January 16]; Available  
493 from: [https://www.who.int/health-topics/coronavirus#tab=tab\\_3](https://www.who.int/health-topics/coronavirus#tab=tab_3).
- 494 8. World Health Organization, W.H. *Coronavirus disease 2019 (COVID-19): situation*  
495 *report, 46*. 2020; Available from: <https://apps.who.int/iris/handle/10665/331443>.
- 496 9. Hongjun Zhao , X.L., Yibin Deng, Yujin Tang, Jiachun Lu, *COVID-19:*  
497 *asymptomatic carrier transmission is an underestimated problem*. Epidemiology and  
498 Infection, 2020. **148**(June 11, 2020).

- 499 10. Wolfel, R., et al., *Virological assessment of hospitalized patients with COVID-2019*.  
500 Nature, 2020. **581**(7809): p. 465-469.
- 501 11. Lauren M. Kucirka, S.A.L., Oliver Laeyendecker, Denali Boon, Justin Lessler,  
502 *Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain*  
503 *Reaction-Based SARS-CoV-2 Tests by Time Since Exposure*. Annals of Internal  
504 Medicine, May 13, 2020. **173**: p. 262-267.
- 505 12. World Health Organization, W.H. *Antigen-detection in the diagnosis of SARS-CoV-2*  
506 *infection using rapid immunoassays*. September 11, 2020; Available from:  
507 [https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays)  
508 [cov-2infection-using-rapid-immunoassays](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays).
- 509 13. FIND. *SARS-CoV-2 diagnostic pipeline*. 2020 [cited 2021 January 16]; Available  
510 from: [https://www.finddx.org/covid-](https://www.finddx.org/covid-19/pipeline/?avance=all&type=all&test_target=Antibody&status=CE-IVD&section=immunoassays&action=default%23diag_tab)  
511 [19/pipeline/?avance=all&type=all&test\\_target=Antibody&status=CE-](https://www.finddx.org/covid-19/pipeline/?avance=all&type=all&test_target=Antibody&status=CE-IVD&section=immunoassays&action=default%23diag_tab)  
512 [IVD&section=immunoassays&action=default%23diag\\_tab](https://www.finddx.org/covid-19/pipeline/?avance=all&type=all&test_target=Antibody&status=CE-IVD&section=immunoassays&action=default%23diag_tab).
- 513 14. Montesinos, I., et al., *Evaluation of two automated and three rapid lateral flow*  
514 *immunoassays for the detection of anti-SARS-CoV-2 antibodies*. J Clin Virol, 2020.  
515 **128**: p. 104413.
- 516 15. Van Elslande, J., et al., *Diagnostic performance of seven rapid IgG/IgM antibody*  
517 *tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients*. Clin Microbiol  
518 Infect, 2020. **26**(8): p. 1082-1087.
- 519 16. Shah, V.K., et al., *Overview of Immune Response During SARS-CoV-2 Infection:*  
520 *Lessons From the Past*. Front Immunol, 2020. **11**: p. 1949.
- 521 17. Liu Ying, L.Y.-p., Diao Bo, Ren Feifei, Wang Yue, Ding Jinya, Huang Qianchuan,  
522 *Diagnostic Indexes of a Rapid IgG/IgM Combined Antibody Test for SARS-CoV-2*.  
523 medRxiv, March 26, 2020.

- 524 18. Pingping Zhang, Q.G., Tang Wang, Yuehua Ke, Fei Mo, Ruizhong Jia, Wanbing Liu,  
525 Lei Liu, Shangen Zheng, Yuzhen Liu, Luping Li, Yao Wang, Lei Xu, Kun Hao, Ruifu  
526 Yang, Shiyue Li, Changqing Lin, Yong Zhao, *Evaluation of recombinant*  
527 *nucleocapsid and spike proteins for serological diagnosis of novel coronavirus*  
528 *disease 2019 (COVID-19)*. medRxiv, 2020. **20036954**.
- 529 19. Gunther, N. and G.W. Hoffmann, *Qualitative dynamics of a network model of*  
530 *regulation of the immune system: a rationale for the IgM to IgG switch*. J Theor Biol,  
531 1982. **94**(4): p. 815-22.
- 532 20. Long, Q.X., et al., *Antibody responses to SARS-CoV-2 in patients with COVID-19*.  
533 Nat Med, 2020. **26**(6): p. 845-848.
- 534 21. Lou, B., et al., *Serology characteristics of SARS-CoV-2 infection after exposure and*  
535 *post-symptom onset*. Eur Respir J, 2020. **56**(2).
- 536 22. Okba, N.M.A., et al., *Severe Acute Respiratory Syndrome Coronavirus 2-Specific*  
537 *Antibody Responses in Coronavirus Disease Patients*. Emerg Infect Dis, 2020. **26**(7):  
538 p. 1478-1488.
- 539 23. Pan, Y., et al., *Serological immunochromatographic approach in diagnosis with*  
540 *SARS-CoV-2 infected COVID-19 patients*. J Infect, 2020. **81**(1): p. e28-e32.
- 541 24. Zhao, J., et al., *Antibody Responses to SARS-CoV-2 in Patients With Novel*  
542 *Coronavirus Disease 2019*. Clin Infect Dis, 2020. **71**(16): p. 2027-2034.
- 543 25. Duan, K., et al., *Effectiveness of convalescent plasma therapy in severe COVID-19*  
544 *patients*. Proc Natl Acad Sci U S A, 2020. **117**(17): p. 9490-9496.
- 545 26. Kirsten E. Wiens , P.N.M., John Rumunu , Damien Slater , Forrest K. Jones , Serina  
546 Moheed , Andrea Caffish , Bior K. Bior , Iboyi Amany Jacob , Richard Lino Loro  
547 Lako , Argata Guracha Guyo , Olushayo Oluseun Olu , Sylvester Maleghemi ,  
548 Andrew Baguma, Juma John Hassen , Sheila K. Baya , Lul Deng , Justin Lessler ,


- 549 Maya N. Demby , Vanessa Sanchez , Rachel Mills , Clare Fraser , Richelle C.  
550 Charles, Jason B. Harris , Andrew S. Azman<sup>1</sup>, Joseph F. Wamala, *Seroprevalence of*  
551 *anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study.*  
552 medRxiv[Preprint], 2021.
- 553 27. Ngoi, J.M., et al., *Genomic analysis of SARS-CoV-2 reveals local viral evolution in*  
554 *Ghana.* Exp Biol Med (Maywood), 2021. **246**(8): p. 960-970.
- 555 28. Oremus, M., et al., *A Computer-Assisted Personal Interview App in Research*  
556 *Electronic Data Capture for Administering Time Trade-off Surveys (REDCap):*  
557 *Development and Pretest.* JMIR Form Res, 2018. **2**(1): p. e3.
- 558 29. Team, R.C. *The R Project for Statistical Computing.* 2020; Available from:  
559 <https://www.r-project.org/index.html>.
- 560 30. Team, R., *RStudio.* 2020.
- 561 31. GraphPad. *GraphPad Software.* 2020; Available from: <https://www.graphpad.com/>.
- 562 32. 3news.com. *Many of Covid-19 cases still among the middle, upper middle class –*  
563 *GHS.* 2021; Available from: [https://3news.com/many-of-covid-19-cases-still-among-](https://3news.com/many-of-covid-19-cases-still-among-the-middle-upper-middle-class-ghs/)  
564 [the-middle-upper-middle-class-ghs/](https://3news.com/many-of-covid-19-cases-still-among-the-middle-upper-middle-class-ghs/).
- 565 33. Afriyie, D.K., et al., *COVID-19 pandemic in resource-poor countries: challenges,*  
566 *experiences and opportunities in Ghana.* J Infect Dev Ctries, 2020. **14**(8): p. 838-843.
- 567 34. Arnold, M.E., et al., *Evaluation of the sensitivity of faecal sampling for detection of*  
568 *monophasic Salmonella Typhimurium and other Salmonella in cattle and pigs.*  
569 Epidemiol Infect, 2015. **143**(8): p. 1681-91.
- 570 35. Deckert, A., T. Barnighausen, and N.N. Kyei, *Simulation of pooled-sample analysis*  
571 *strategies for COVID-19 mass testing.* Bull World Health Organ, 2020. **98**(9): p. 590-  
572 598.

- 573 36. PILLA, V. *Coronavirus pandemic: 'Pool testing' for COVID-19 may benefit India as*  
574 *US study proves test feasibility, efficacy.* April 6, 2020; Available from:  
575 [https://www.moneycontrol.com/news/coronavirus/coronavirus-pandemic-pool-](https://www.moneycontrol.com/news/coronavirus/coronavirus-pandemic-pool-testing-for-covid-19-may-benefit-india-as-us-study-highlights-test-feasibility-5111811.html)  
576 [testing-for-covid-19-may-benefit-india-as-us-study-highlights-test-feasibility-](https://www.moneycontrol.com/news/coronavirus/coronavirus-pandemic-pool-testing-for-covid-19-may-benefit-india-as-us-study-highlights-test-feasibility-5111811.html)  
577 [efficacy-5111811.html](https://www.moneycontrol.com/news/coronavirus/coronavirus-pandemic-pool-testing-for-covid-19-may-benefit-india-as-us-study-highlights-test-feasibility-5111811.html).
- 578 37. Van, T.T., et al., *Pooling nasopharyngeal/throat swab specimens to increase testing*  
579 *capacity for influenza viruses by PCR.* J Clin Microbiol, 2012. **50**(3): p. 891-6.
- 580 38. Worldometer. *Coronavirus Update (Live).* 2020 [cited 2021 February 2]; Available  
581 from: <https://www.worldometers.info/coronavirus/#countries>.
- 582 39. Emmanuel Komla Junior Dzisi, O.A.D., *Adherence to social distancing and wearing*  
583 *of masks within public transportation during the COVID 19 pandemic.* Transportation  
584 Research Interdisciplinary Perspectives, 2020. **7**(September).
- 585 40. Graphic.com.gh. *COVID-19 prevention in Ghana: 82% not wearing face masks -*  
586 *Survey - Graphic Online.* 2020; Available from:  
587 [https://www.graphic.com.gh/news/general-news/covid-19-accra-not-wearing-face-](https://www.graphic.com.gh/news/general-news/covid-19-accra-not-wearing-face-masks-survey.html)  
588 [masks-survey.html](https://www.graphic.com.gh/news/general-news/covid-19-accra-not-wearing-face-masks-survey.html).
- 589 41. NICD, *COVID-19 SPECIAL PUBLIC HEALTH SURVEILLANCE BULLETIN B.*  
590 Brooke, Editor. 2020.
- 591 42. Chibwana, M.G., et al., *High SARS-CoV-2 seroprevalence in Health Care Workers*  
592 *but relatively low numbers of deaths in urban Malawi.* medRxiv, 2020.
- 593 43. Uyoga, S., et al., *Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood*  
594 *donors.* Science, 2021. **371**(6524): p. 79-82.
- 595 44. Chen, X., et al., *Serological evidence of human infection with SARS-CoV-2: a*  
596 *systematic review and meta-analysis.* Lancet Glob Health, 2021. **9**(5): p. e598-e609.



- 597 45. voanews.com. *Fears Grow of Further COVID-19 Spikes Ahead of Ghana's Election.*  
598 2020; Available from: [https://www.voanews.com/africa/fears-grow-further-covid-19-  
600 spikes-ahead-ghanas-election](https://www.voanews.com/africa/fears-grow-further-covid-19-<br/>599 spikes-ahead-ghanas-election).
- 600 46. Nkuba Ndaye, A., et al., *Challenges in interpreting SARS-CoV-2 serological results*  
601 *in African countries.* Lancet Glob Health, 2021. **9**(5): p. e588-e589.
- 602 47. Yadouleton, A., et al., *Limited Specificity of Serologic Tests for SARS-CoV-2*  
603 *Antibody Detection, Benin.* Emerg Infect Dis, 2021. **27**(1).
- 604 48. Tso, F.Y., et al., *High prevalence of pre-existing serological cross-reactivity against*  
605 *severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan*  
606 *Africa.* Int J Infect Dis, 2021. **102**: p. 577-583.
- 607 49. Al-Jighefee, H.T., H.M. Yassine, and G.K. Nasrallah, *Evaluation of Antibody*  
608 *Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic*  
609 *Assessment of New IgM/IgG ELISA Kits.* Pathogens, 2021. **10**(2).
- 610 50. *Corrigendum to SARS-CoV-2 Serology: Much Hype, Little Data.* Clin Chem, 2020.  
611 **66**(12): p. 1574.  
612


613 **Supplemental Files**



614

615 **Figure S1. Venn Diagram showing distribution of participants and sites across the**  
616 **different Phases of the study.** GAR refers to the Greater Accra Region, CR refers to the  
617 Central Region and UER refers to the Upper East Region.


618



619

620 **Figure S2: Representative pictures of study cassettes showing (A) Positive IgG, (B)**  
621 **Positive IgM\*, (C) Combined positive IgM/IgG and (D) antibody negative test results.**


622 \*Pictures of IgM are from patients, not from field due to low incidence of IgM only observed  
623 in the field and faintness of igM bands in the field



624

625 **Figure S3: Summary of Phase I participants' knowledge of (A) COVID-19 symptoms,**  
 626 **(B) mode of transmission and (C) prevention**

627



628

629 **Figure S4: Participants who had previously taken a PCR test that detects SARS-CoV-2**

630



631

632

633

634


635



636

637 **Figure S4: Regressional analysis of Phase II and III exposure rates**

638



639

640 **Figure S5: Regressional analysis of results of Phase IV exposure rates**

641